Large Genomic Study Identifies New Pancreatic Cancer Risk Loci
By LabMedica International staff writers Posted on 05 Mar 2018 |
Image: A Manhattan plot of the study results show taller peaks that denote genetic loci most significantly associated with pancreatic cancer risk (Photo courtesy of Dr. Alison Klein, Johns Hopkins University).
A large genome-wide association study (GWAS) identified five new susceptibility loci for pancreatic cancer.
Pancreatic cancer is among the leading causes of cancer death in the U.S. and Europe and is expected to result in nearly 150,000 annual deaths by 2020. To identify common susceptibility alleles, a consortium of more than 80 research institutions performed one of the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4).
Overall, investigators analyzed more than 11.3 million variants in 21,536 individuals.
The newly identified loci were found on human chromosomes one (position 1p36.33), 7 (position 7p12), eight (position 8q21.11), 17 (position 17q12), and 18 (position 18q21.32). The increased risk of developing pancreatic cancer was estimated to be from 15 to 25% for each copy present in the genome.
"On an individual level, having one of these variants is not very predictive of cancer, in that they are only associated with a modest change in risk, but when taken together, they help to create the fuller picture of how pancreatic cancer develops," said first author Dr. Alison Klein, professor of oncology, pathology, and epidemiology at Johns Hopkins University (Baltimore, MD, USA). "Continuing studies will delve deeper into the genetics of pancreatic cancer. There is still a lot more that we do not know about hereditary factors in pancreatic cancer risk."
The pancreatic cancer genome-wide association study was published in the February 8, 2018, online edition of the journal Nature Communications.
Related Links:
Johns Hopkins University
Pancreatic cancer is among the leading causes of cancer death in the U.S. and Europe and is expected to result in nearly 150,000 annual deaths by 2020. To identify common susceptibility alleles, a consortium of more than 80 research institutions performed one of the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4).
Overall, investigators analyzed more than 11.3 million variants in 21,536 individuals.
The newly identified loci were found on human chromosomes one (position 1p36.33), 7 (position 7p12), eight (position 8q21.11), 17 (position 17q12), and 18 (position 18q21.32). The increased risk of developing pancreatic cancer was estimated to be from 15 to 25% for each copy present in the genome.
"On an individual level, having one of these variants is not very predictive of cancer, in that they are only associated with a modest change in risk, but when taken together, they help to create the fuller picture of how pancreatic cancer develops," said first author Dr. Alison Klein, professor of oncology, pathology, and epidemiology at Johns Hopkins University (Baltimore, MD, USA). "Continuing studies will delve deeper into the genetics of pancreatic cancer. There is still a lot more that we do not know about hereditary factors in pancreatic cancer risk."
The pancreatic cancer genome-wide association study was published in the February 8, 2018, online edition of the journal Nature Communications.
Related Links:
Johns Hopkins University
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans